EUVIMEDEUVIMED entdecken
Crossref

An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting

Gerald M Cherf, Robert B Lee, Nishant Mehta, Claire Clifford, Kathleen Torres, James R Kintzing, Jennifer R Cochran iD

Biotechnology and Bioengineering · 2024

DOI: 10.1002/bit.28790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2024. Verfasst von Gerald M Cherf und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Receptors, Urokinase Plasminogen Activator. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urokinase‐type plasminogen activator receptor (uPAR) is overexpressed on tumor cells in multiple types of cancer and contributes to disease progression and metastasis. In this work, we engineered a novel bi‐paratopic uPAR targeting agent by fusing the binding domains of two native uPAR ligands: uPA and vitronectin, with a flexible peptide linker. The linker length was optimized to facilitate simultaneous engagement of both domains to their adjacent epitopes on uPAR, resulting in a high affinity and avid binding interaction. Furthermore, the individual domains were affinity‐matured using yeast surface display and directed evolution, resulting in a bi‐paratopic protein with affinity in the picomolar to femtomolar range. This engineered uPAR targeting agent demonstrated significantly enhanced tumor localization in mouse tumor models compared to the native uPAR ligand and warrants further investigation as a diagnostic and therapeutic agent for cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Urokinase Plasminogen ActivatorAnimalsMiceHumansProtein EngineeringUrokinase-Type Plasminogen ActivatorCell Line, TumorNeoplasmsVitronectinRecombinant Fusion Proteins

Stichwörter der Autor:innen

Fc‐fusionbi‐paratopic ligandprotein engineeringtumor targetingurokinase‐type plasminogen activator receptoryeast surface display

Substanzen

Receptors, Urokinase Plasminogen ActivatorUrokinase-Type Plasminogen ActivatorVitronectinRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Bioengineering, Stanford University, Stanford, California, USA.
  • Department of Chemical Engineering, Stanford University, Stanford, California, USA.
  • Stanford Cancer Institute, Stanford University, Stanford, California, USA.

ORCID-Profile: Jennifer R Cochran

Zitieren

APA

Cherf, G. M., Lee, R. B., Mehta, N., Clifford, C., Torres, K., Kintzing, J. R., & Cochran, J. R. (2024). An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28790

Vancouver

Cherf GM, Lee RB, Mehta N, Clifford C, Torres K, Kintzing JR, et al. An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28790

BibTeX
@article{Cherf2024,
  author = {Cherf, Gerald M and Lee, Robert B and Mehta, Nishant and Clifford, Claire and Torres, Kathleen and Kintzing, James R and Cochran, Jennifer R},
  title = {An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting},
  journal = {Biotechnology and Bioengineering},
  year = {2024},
  doi = {10.1002/bit.28790}
}
Kostenlos starten →